Drug companies "boosted their lobbying in Washington during the three months (that) ended June 30 amid a flurry of congressional action on health care," while overall, "Washington"s lobbying business continued to slump as the economy pinched budgets at some big companies and trade associations," The Wall Street Journal reports. "Drug manufacturers increased lobbying spending 13% to $68 million in the second quarter from a year earlier, according to the data ò€¦ Overall, the health-care sector reported a 5% increase in lobbying expenditures to $133 million, making it the single largest spender on lobbying of the 10 major industry sectors tracked by the Center for Responsive Politics. Health-insurance companies increased lobbying activity by 11% to $7.8 million, according to the data" (Mullins and Farnam, 8/3).